REFRACTORY MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA
Clinical trials for REFRACTORY MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental antibody takes aim at tough lymphoma
Disease control OngoingThis early-phase trial is testing an experimental antibody called MEDI-570 in 21 people with certain types of T-cell lymphoma that have come back or not responded to treatment. The goal is to find the safest dose and see how the body handles the drug. MEDI-570 works by targeting …
Matched conditions: REFRACTORY MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo shows promise for rare blood cancer
Disease control OngoingThis early-stage study tested a combination of two drugs (pembrolizumab and pralatrexate) in 13 people with peripheral T-cell lymphoma that had returned or not responded to prior treatment. The goal was to find the safest dose and see if the combo could shrink tumors. The approac…
Matched conditions: REFRACTORY MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Cancer-Fighting virus teams up with immunotherapy to tackle rare skin tumors
Disease control OngoingThis phase II trial is testing whether a combination of talimogene laherparepvec (a modified herpes virus that infects and kills cancer cells) and nivolumab (an immunotherapy drug) can shrink tumors in people with rare skin cancers or lymphomas that haven't responded to standard …
Matched conditions: REFRACTORY MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Two-Drug attack on tough lymphoma shows promise in early trial
Disease control OngoingThis study tests whether combining two drugs—pembrolizumab (Keytruda), which helps the immune system fight cancer, and romidepsin (Istodax), which blocks cancer cell growth—can safely treat peripheral T-cell lymphoma that has returned or not responded to prior therapy. The trial …
Matched conditions: REFRACTORY MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC